rVSV-HCV Envelope Vaccine Particles for Broad Strain Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for hepatitis C virus (HCV) do not effectively induce broadly neutralizing antibodies and fail to account for the genetic variability of HCV strains, lacking a robust animal model for testing and often relying on genotype-specific systems that may not represent the full diversity of globally sampled HCV strains.
Innovation Solution
A composition comprising the 60 C-terminal amino acids of the HCV core protein, HCV E1 and E2 proteins from specific strains (GT2a.J6, GT2r.2r, or GT5a.SA13), and VSV-G protein, assembled into rVSV-HCV pseudovirus particles, which induce cross-reactive neutralizing antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If genotype-specific vaccine systems are used, then vaccine development is simplified, but the vaccine fails to protect against diverse HCV strains
Solution Approach 1:
The patent uses a universal VSV vector platform that can accommodate multiple HCV envelope protein variants. The VSV-G pseudotyping creates a universal delivery system that presents diverse HCV antigens in a standardized format, enabling broad protection while maintaining manufacturing simplicity through a single vector backbone.
Solution Approach 2:
The invention combines VSV structural proteins with HCV envelope proteins (E1/E2) from multiple genotypes to create composite pseudoparticles. This composite structure leverages the stable VSV core for consistent manufacturing while incorporating diverse HCV antigens for broad strain coverage.
2Measurement precision
If HCV pseudoparticles are used for testing, then testing capability is improved, but the models lack robustness for direct protection assessment
Solution Approach 1:
The patent uses VSV pseudoparticles as an intermediary testing system that bridges in vitro neutralization assays and in vivo protection studies. The pseudoparticles maintain HCV antigenicity while providing a standardized, controllable platform for measuring antibody responses, which can then be validated in animal models expressing human HCV receptors.
Solution Approach 2:
The invention creates simplified copies of HCV particles using VSV structural framework and HCV envelope proteins. These pseudoparticle copies retain the essential neutralization epitopes of authentic HCV while being easier to produce and standardize for consistent testing across different genotypes.
3Speed
If VSV-G pseudotyping is used, then cell entry efficiency is improved, but dependency on human-specific receptors limits applicability
Solution Approach 1:
The patent applies VSV-G pseudotyping locally to the surface of HCV pseudoparticles, creating a dual-mechanism entry system. The VSV-G provides efficient initial attachment and membrane fusion, while the HCV envelope proteins provide specificity for human liver receptors, optimizing both entry speed and target specificity in human cells.
Data Source
AI summary
The present invention relates to the field of vaccination, in particular, of vaccination against hepatitis C virus (HCV). The present invention provides a composition comprising at least parts of the HCV core protein, and HCV E1 and HCV E2 protein of a specific HCV strain, as well as VSV-G protein. The proteins may be assembled in rVSV-HCV particles. This has been identified to induce particularly advantageous broadly neutralizing antibodies. The invention further provides nucleic acids encoding said HCV proteins and VSV proteins but not encoding VSV-G protein. Vaccines comprising the particles, compositions or nucleic acids are disclosed as useful, in particular, for prophylactic vaccination against HCV. Methods of producing the rVSV-HCV particles or compositions of the invention and the produced particles and compositions are also subject-matter of the invention.